A phase I, open-label, multicenteir study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS)

被引：0
作者：
Bar-Or, Amit
Calabresi, Peter
Arnold, Douglas
Markowitz, Clyde
Shafer, Stuart
Kasper, Lloyd
Waubant, Emmanuelle
Gazda, Suzanne
Fox, Robert
Sarkar, Neena
Panzara, Michael
Smith, Craig
机构：
来源：
NEUROLOGY | 2007年 / 68卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [11] Safety and tolerability of fingolimod in relapsing-remitting multiple sclerosis: results from a large open-label clinical trial
    Laroni, A.
    Brogi, D.
    Morra, V. Brescia
    Guidi, L.
    Pozzilli, C.
    Comi, G.
    Lugaresi, A.
    Turrini, R.
    Raimondi, D.
    Uccelli, A.
    Mancardi, G. L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 104 - 105
  • [12] Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
    Laroni, Alice
    Brogi, Davide
    Morra, Vincenzo Brescia
    Guidi, Leonello
    Pozzilli, Carlo
    Comi, Giancarlo
    Lugaresi, Alessandra
    Turrini, Renato
    Raimondi, Debora
    Uccelli, Antonio
    Mancardi, Giovanni Luigi
    NEUROLOGICAL SCIENCES, 2017, 38 (01) : 53 - 59
  • [13] Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
    Alice Laroni
    Davide Brogi
    Vincenzo Brescia Morra
    Leonello Guidi
    Carlo Pozzilli
    Giancarlo Comi
    Alessandra Lugaresi
    Renato Turrini
    Debora Raimondi
    Antonio Uccelli
    Giovanni Luigi Mancardi
    Neurological Sciences, 2017, 38 : 53 - 59
  • [14] Safety and tolerability of ALKS 8700 in relapsing-remitting multiple sclerosis: Phase 3 open-label study design (EVOLVE-MS-1)
    Naismith, R. T.
    Claxton, A. E.
    Leigh-Pemberton, R. A.
    Du, Y.
    Hard, M. L.
    von Moltke, L.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 372 - 372
  • [15] QualiCOP: an open-label, prospective, observational study of glatiramer acetate in patients with relapsing-remitting multiple sclerosis
    Ziemssen, T.
    Calabrese, P.
    Penner, I. -K.
    Carroll, C. A.
    Apfel, R.
    JOURNAL OF NEUROLOGY, 2014, 261 : S229 - S229
  • [16] Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
    Jai Perumal
    Roumen Balabanov
    Ray Su
    Roger Chang
    Laura Balcer
    Steven Galetta
    Denise I. Campagnolo
    Robin Avila
    Lily Lee
    Danette Rutledge
    Robert J. Fox
    Advances in Therapy, 2021, 38 : 3743 - 3744
  • [17] Erratum to: Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
    Laura Ordoñez-Boschetti
    Roberto Rey
    Ana Cruz
    Arijit Sinha
    Tracy Reynolds
    Nadina Frider
    Regina Alvarenga
    Advances in Therapy, 2015, 32 : 636 - 636
  • [18] QualiCOP: an open-label, prospective, observational study of glatiramer acetate in patients with relapsing-remitting multiple sclerosis
    Ziemssen, T.
    Calabrese, P.
    Penner, I. -K.
    Carroll, C. A.
    Apfel, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 340 - 340
  • [19] EVOLVE-MS-1: Phase 3 Open-Label Long-Term Safety Study of ALKS 8700 in Relapsing-Remitting Multiple Sclerosis
    Naismith, Robert
    Leigh-Pemberton, Richard
    Claxton, Amy
    Du, Yangchun
    Hard, Marjie
    von Moltke, Lisa
    Wolinsky, Jerry
    NEUROLOGY, 2017, 88
  • [20] EVOLVE-MS-1: a phase 3, open-label, long-term safety study of ALKS 8700 in relapsing-remitting multiple sclerosis
    Naismith, R. T.
    Leigh-Pemberton, R. A.
    Rezendes, D.
    Ge, T.
    von Moltke, L.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 617 - 617
12345